Ajay Royan Buys 23,000 Shares of Fractyl Health (NASDAQ:GUTS) Stock

Posted by Francis Steltz on Jun 15th, 2026

Fractyl Health, Inc. (NASDAQ:GUTS – Get Free Report) Director Ajay Royan purchased 23,000 shares of Fractyl Health stock in a transaction on Friday, June 12th. The stock was bought at an average cost of $0.85 per share, with a total value of $19,550.00. Following the completion of the acquisition, the director owned 40,901 shares in the company, valued at approximately $34,765.85. This trade represents a 128.48% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link.

Fractyl Health Stock Performance

Shares of NASDAQ:GUTS remained flat at $0.85 on Monday. 1,732,242 shares of the stock traded hands, compared to its average volume of 3,947,680. The firm’s 50 day moving average price is $0.70 and its 200 day moving average price is $1.06. The stock has a market capitalization of $134.85 million, a price-to-earnings ratio of -0.66 and a beta of 2.34. The company has a debt-to-equity ratio of 1.41, a current ratio of 4.28 and a quick ratio of 4.28. Fractyl Health, Inc. has a one year low of $0.38 and a one year high of $2.45.

Fractyl Health (NASDAQ:GUTS – Get Free Report) last released its earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.23. Research analysts predict that Fractyl Health, Inc. will post -0.6 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GUTS. Jane Street Group LLC acquired a new stake in Fractyl Health during the second quarter valued at approximately $31,000. FNY Investment Advisers LLC bought a new position in shares of Fractyl Health during the 3rd quarter worth approximately $31,000. Jump Financial LLC bought a new position in shares of Fractyl Health during the 4th quarter worth approximately $57,000. Scientech Research LLC acquired a new stake in Fractyl Health in the 3rd quarter valued at $49,000. Finally, Prelude Capital Management LLC acquired a new stake in Fractyl Health in the 3rd quarter valued at $55,000.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on GUTS shares. Wall Street Zen raised Fractyl Health from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a research note on Thursday, June 4th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a research report on Thursday, March 26th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Fractyl Health in a research note on Tuesday, May 12th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $5.40.

Get Our Latest Research Report on Fractyl Health

Fractyl Health Company Profile

(Get Free Report)

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.